Oxytocin has two lives, and the side-effect record splits along the line between them. As Pitocin, it is an FDA-labelled intravenous drug given in hospital to start or strengthen labour and to control bleeding after birth. As a nasal spray, it is a research tool and an online product sold for mood, bonding and social anxiety — with no approved US product at all.
The label figures and the dose arithmetic are on our oxytocin dosage page; what the hormone is and does is on Peptide Lexicon's oxytocin entry. This page sets the two safety records side by side.
The labour-ward record
The current PITOCIN label (Par Health, effective 6 May 2026) lists its maternal adverse reactions without frequencies:
- anaphylactic reaction; premature ventricular contractions; cardiac arrhythmia
- postpartum haemorrhage; pelvic haematoma; subarachnoid haemorrhage
- fatal afibrinogenemia (loss of a clotting protein)
- hypertensive episodes; nausea; vomiting
- rupture of the uterus
For the fetus or newborn it lists bradycardia and other arrhythmias, low five-minute Apgar scores, neonatal jaundice, retinal haemorrhage, permanent brain damage, seizures and fetal death. The label attributes several of these to the strength of the contractions the drug induces, not to oxytocin reaching the baby. That is the core mechanism of most of the serious list: overstimulation of the uterus. The label's overdosage section describes hypertonic or tetanic contractions leading to uterine rupture, lacerations, haemorrhage and fetal hypoxia.
The label also carries an important notice that Pitocin is not indicated for elective induction, because the data are inadequate to weigh benefit against risk, and requires continuous observation by trained staff whenever it is infused.
Water intoxication: the one effect not about the uterus
The label calls this "the inherent antidiuretic effect of oxytocin": the hormone acts on the kidney much as vasopressin does, holding back water. It states that severe water intoxication with convulsions and coma has occurred with a slow infusion over 24 hours, that maternal death from it has been reported, and that it is associated with large doses — 40 to 50 milliunits a minute — infused for long periods. For scale, the label's starting rate is 0.5 to 1 milliunit a minute.
This is the effect most relevant outside labour, because it does not depend on a pregnant uterus. It is also the one nobody has measured over long-term nasal use: no trial we found tracked blood sodium across months of daily spray.
What FDA's reports show
openFDA returned 2,983 reports listing oxytocin on 4 October 2026. The top coded terms are:
| Term | Reports |
|---|---|
| Foetal exposure during pregnancy | 442 |
| Maternal exposure during pregnancy | 431 |
| Drug ineffective | 401 |
| Exposure during pregnancy | 361 |
| Premature baby | 206 |
| Hypotension | 191 |
| Off-label use | 191 |
| Postpartum haemorrhage | 144 |
These are reports in which oxytocin appears, often beside many other drugs given during delivery; they are not reports in which it was judged the cause. They describe obstetrics. Not one recorded a nasal route. The database contains effectively nothing about the way oxytocin is sold online.
The nasal-spray record
That record is research. A 2011 systematic review (MacDonald et al.) gathered 38 randomised trials from 1990 to 2010: 1,529 participants, 79% male, doses of 18 to 40 IU, mostly single administrations and at most 182. Its findings: side effects were not different from placebo, participants could not tell whether they had received oxytocin, and three case reports described adverse reactions linked to misuse or longer-term use.
The largest long-term trial since then is SOARS-B (Sikich et al., NEJM 2021): 290 children and adolescents with autism, a target 48 IU a day for 24 weeks, against placebo. Adverse events were similar in incidence and severity in both groups. The trial's main question — whether social withdrawal improved — returned no difference (−3.7 vs −3.5, p = 0.61).
So the nasal evidence says two things at once: at research doses, under supervision, it rarely produced measurable side effects; and in the largest trial it also produced no measurable benefit.
What neither record covers
- Products sold without a label. The US label database holds no nasal prescription oxytocin; the "spray" records it does hold are multi-ingredient homeopathic preparations, as counted on our dosage page. Oxytocin is dosed in USP units, a potency measure, so a vial or spray with no assay behind it has no checkable strength. What testing can and cannot establish is on our peptide testing page.
- Daily use for months or years, in adults, outside a trial.
- Women outside pregnancy, who were about a fifth of the 2011 review's participants.
- Sodium and fluid balance over long-term use.
- Pregnancy — where oxytocin's main documented action is to make the uterus contract.
Anyone using an oxytocin product who develops headache, confusion, nausea or swelling, or who is or may be pregnant, should tell a doctor what the product was and how it was used. How these research-compound records compare with each other is on our peptide side-effects overview.
Sources and dates
- PITOCIN (oxytocin injection) prescribing information, Par Health USA, NDA 018261, via openFDA, effective 2026-05-06: adverse reactions, warnings, precautions, overdosage, contraindications, important notice (read 2026-10-04).
- openFDA drug adverse-event endpoint, generic name oxytocin: total, reaction counts, route 045 (nasal) query (read 2026-10-04).
- MacDonald E et al. Psychoneuroendocrinology 2011;36:1114–26, PMID 21429671 (abstract read 2026-10-04).
- Sikich L et al. N Engl J Med 2021;385:1462–73, PMID 34644471; NCT01944046 (abstract read 2026-10-04).
- DailyMed and openFDA route census for oxytocin as recorded on our oxytocin dosage page (read 2026-09-19).
Corrections go to the contact page.